. Author manuscript; available in PMC: 2017 Jul 4.

Published in final edited form as: Diabetes Metab Res Rev. 2014 Mar;30(3):191–200. doi: 10.1002/dmrr.2466

Table 3.

Histomorphometry analysis of the endosteal surface of femora from the diabetic MKR mice after 8 weeks of treatment

	Vehicle (n = 9)	MK-0626 (n = 8)	Pioglitazone (n = 5)	Alendronate (n = 6)
BFR μm/day	0.37 ± 0.22	0.29 ± 0.17	0.32 ± 0.06	0.15 ± 0.18
MAR μm/day	0.69 ± 0.25	0.75 ± 0.16	0.58 ± 0.11	0.38 ± 0.28
MS/BS%	53.82 ± 18.21	37.03 ± 17.58	55.37 ± 6.4	33.02 ± 17.77
ES/BS%	6.13 ± 2.11	6.40 ± 1.41	3.04 ± 0.86	9.5 ± 1.95 ^*
Ob.N/BS/mm	13.41 ± 1.85	14.68 ± 5.08	15.18 ± 3.33	11.76 ± 3.45
Oc.N/BS/mm	1.81 ± 0.47	1.96 ± 0.44	1.03 ± 0.27 ^*	2.93 ± 0.52 ^*

BFR, μm/day, bone formation rate; MAR, μm/day, mineral apposition rate; MS/BS, %, mineralization surface/bone surface; ES/BS, %, erosion surface/bone surface; Ob.N/BS, mm⁻¹, osteoblast number/bone surface; Oc. N/BS, mm⁻¹,osteoclast number/bone perimeter. Results are expressed as mean values ± SEM.

p value <0.05 between MKR vehicle and other treatment group.